Trump Pushes Expanded Access to Psychedelics Like Psilocybin
Trump’s upcoming federal measures aim to boost psychedelic research and access, signaling a surprising shift in drug policy that could reshape mental health treatment in America.
President Donald Trump is preparing an announcement to significantly increase federal support for psychedelic substances such as psilocybin and ibogaine, according to sources cited by The Washington Post on April 17, 2026. The effort would ease restrictions on research and treatment access, marking a notable pivot for a Republican administration historically cautious on drug policy.
Why This Matters
Psychedelics like psilocybin (the active compound in “magic mushrooms”) and ibogaine have long existed in a legal gray area, classified as Schedule I drugs under the Controlled Substances Act — meaning they are considered to have high abuse potential and no accepted medical use. This has severely limited clinical research despite mounting evidence of their effectiveness in treating depression, PTSD, anxiety, and addiction.
Over the past decade, independent studies and state-level reforms have challenged that classification, pushing a wave of psychedelic research and therapy programs. Notably, Oregon legalized psilocybin therapy in 2020, and cities like Denver and Washington, D.C., have decriminalized personal use. However, federal policy has largely lagged, keeping psychedelic drugs off-limits for most researchers and patients.
Trump’s initiative would break with this status quo by expanding federal funding and easing regulatory hurdles for psychedelic science and therapy programs. It could accelerate the integration of these treatments into mainstream medicine, which many experts view as a crucial frontier for the mental health crisis. According to data from the National Institute of Mental Health, nearly 30 million U.S. adults suffer from major depressive disorder, yet only half receive adequate treatment. Psychedelic-assisted therapies show promise of durable benefits for treatment-resistant cases.
There’s also a strong economic angle. The psychedelic medicine market is projected to hit $7 billion by 2030, fueled by growing public acceptance and research breakthroughs. Federal support under a Trump administration could stimulate private investment and drug development pipelines notably, positioning the U.S. at the forefront of a potentially transformative biotech sector.
What’s Behind the Shift?
This policy move surprises given Trump’s prior administrations’ tough stance on drugs. Sources suggest this pivot is driven by lobbying from biotech firms, mental health advocates, and veteran groups emphasizing psychedelics’ potential to address opioid addiction and PTSD—a key concern for veterans’ health. It reflects broader bipartisan convergence seen in Congress on the issue and mirrors a shifting public opinion landscape: Gallup polling in 2025 found 61% of Americans support legal medical use of psychedelics.
Moreover, Trump’s competitive 2024 comeback and 2026 presidential ambitions may factor in. Adopting a progressive yet pragmatic approach on mental health and drug reform could broaden his base, appealing to younger voters and disillusioned moderate conservatives.
What to Watch Next
The key questions involve the details and scope of the forthcoming order:
- Will it reschedule psychedelics to facilitate medical use or merely loosen research restrictions?
- How durable will these reforms be amid opposition from conservative lawmakers and federal agencies like the DEA?
- How quickly can psychedelics transition from experimental therapies to FDA-approved medicines?
State-level reforms might accelerate in response, while pharmaceutical companies and academic institutions gear up for increased opportunities. A constructive next signpost will be the administration’s appointment choices to lead relevant agencies such as the FDA and National Institute on Drug Abuse.
This development isn’t just a shift in drug policy; it’s a potential inflection point for U.S. mental health strategy, innovation, and federal regulatory culture. By expanding psychedelic access, Trump’s administration could help pivot the country away from punitive drug laws toward evidence-based treatment — a political and social gamble with wide-reaching consequences.
For more on the evolving U.S. political landscape and drug policy, visit 
United States and US Politics.
Trump to expand federal support for psychedelic research
